Claudin-1 / EGFR bispecific antibodies for targeted degradation
TW202629242APending Publication Date: 2026-07-16ALENTIS THERAPEUTICS AG
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- TW114135012
- Authority / Receiving Office
- TW · TW
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-09-12
- Filing Date
- 2025-09-11
- Publication Date
- 2026-07-16
Abstract
The present disclosure relates to bispecific antibodies that bind Claudin 1 and EGFR and their use in treating diseases, for example, cancer.
Need to check novelty before this filing date? Find Prior Art